全球疫苗市場：2008年至2023年

全球疫苗市場：2008年至2023年 是由出版商Visiongain在2008年08月所出版的。 這份英文市場調查報告書包含196 pages 價格從美金2331起跳。

簡介

封面圖片：

目錄

Abstract

The period 2008-2023 will see a vaccine “boost”. There will be a new resurgence in the sales and utilisation of vaccines. Are you prepared for this? You should be.

During this period, vaccines will be one of the fastest growing segments of the pharmaceutical market. Vaccine revenues will increase in size by several hundred percent between 2007 and 2023. This brand new in-depth report The Global Vaccines Market, 2008-2023 describes trends in the market both quantitatively and qualitatively. In recent years, this global vaccines market has undergone a renaissance, as the importance of vaccines in both developed and developing nations becomes underlined by epidemiological patterns and healthcare needs.

The key growth driver for vaccines is their cost-effectiveness in combating disease. This situation will encourage greater use of vaccines by governments and private healthcare providers. New disease targets that could be mitigated through vaccination, including high profile (and potentially profitable) targets such as cancer. Visiongain notes that many healthcare providers are viewing preventative medicine enthusiastically, being aware of the significant increases in quality of life and reduction of healthcare expenditure that can result from prophylaxis. The vaccines industry is responding with innovative products, making full use of technological advances in biotechnology. This market has great developmental potential, both therapeutically and commercially. There are currently more than 1000 vaccines in research and development worldwide.

• Sales forecasts for vaccines by disease area, brand and country, including novel therapeutic vaccines
• Examination of strengths, weakness, opportunities and threats facing the vaccine industry
• Expert opinion from key-opinion leaders in the field
• In-depth analysis of the vaccine pipeline
• Analysis of the prospects for therapeutic vaccines
• Geographical breakdown of the vaccine market, including the leading emerging markets of China and India
• Coverage of future trends in vaccine technology, formulation and manufacturing
• Identification of key industrial players in the vaccines market.

The Global Vaccines Market, 2008-2023 examines the vaccines market comprehensively, using unique primary and secondary research. The report includes full transcripts of interview - you cannot get this information anywhere else.

Also included are company reports, filings and industry databases. Exclusively, visiongain have applied their in-house analytical techniques for financial forecasting and analysis of drivers and restraints. Now available to you this comprehensive market-based report with detailed analyses, forecasts and informed opinion is essential to your vaccine market development.

Therapeutic vaccines differ from currently-marketed vaccines. Instead of simply preventing infection from disease, therapeutic vaccines work with the body' s immune system to fight diseases and disorders, including cancer, addiction and allergies. Their therapeutic and commercial potential is vast. Visiongain predicts that therapeutic vaccines will significantly expand the market for vaccines, contributing to rapid revenue growth during the period 2008 to 2023.

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for vaccines, including key metrics and predicted revenues, by vaccine disease area and leading brand
• To receive forecasts of vaccine sales in leading country markets from 2008-2023, including China and India
• To discover the views of experts in the vaccines sector
• To determine the forces that influence the market for vaccines: drivers, restraints, opportunities and threats
• To find out where the vaccines market is heading - both technologically and commercially from 2008 to 2023.

Table of Contents

1. Executive Summary

2. Vaccines and Vaccine-Preventable Diseases

• 2.1 Immunisation and Types of Vaccine
  • 2.1.1 Vaccines: A Healthcare Triumph
  • 2.1.2 The Immune System and Natural Immunity
  • 2.1.3 Edward Jenner Laid the Foundation for Modern Vaccines
  • 2.1.4 Vaccines Work by Creating Artificial Immunity
  • 2.1.5 Vaccine Formulation
  • 2.1.6 Types of Vaccine
    • 2.1.6.1 Classification of Vaccines
    • 2.1.6.2 Live, Attenuated Vaccines
    • 2.1.6.3 Recombinant Live Vaccines
    • 2.1.6.4 Inactivated Vaccines
    • 2.1.6.5 Toxoid Vaccines
    • 2.1.6.6 Subunit Vaccines
    • 2.1.6.7 Conjugate Vaccines
    • 2.1.6.8 Recombinant Subunit Vaccines
    • 2.1.6.9 DNA Vaccines
    • 2.1.6.10 Recombinant Vector Vaccines
• 2.2 Vaccine Preventable Diseases
  • 2.2.1 Cervical Cancer/Human Papillomavirus (HPV)
  • 2.2.2 Chickenpox and Shingles
  • 2.2.3 Cholera
  • 2.2.4 Diphtheria
  • 2.2.5 Haemophilus influenzae Type b (Hib) Diseases
  • 2.2.6 Hepatitis A
  • 2.2.7 Hepatitis B
  • 2.2.8 Influenza
    • 2.2.8.1 Influenza Prevalence
    • 2.2.8.2 The Influenza Virus
    • 2.2.8.3 Influenza Pandemics and Avian Influenza
    • 2.2.8.4 Influenza Vaccination
  • 2.2.9 Japanese Encephalitis
  • 2.2.10 Measles
  • 2.2.11 Meningococcal Diseases
  • 2.2.12 Mumps
  • 2.2.13 Pertussis
  • 2.2.14 Polio
  • 2.2.15 Rotavirus Diseases
  • 2.2.16 Rubella
  • 2.2.17 Streptococcus Pneumoniae Infections
  • 2.2.18 Tetanus
  • 2.2.19 Tick-Borne Encephalitis
  • 2.2.20 Tuberculosis
  • 2.2.21 Typhoid
  • 2.2.22 Yellow Fever
• 2.3 Top-Selling Vaccines in 2007
  • 2.3.1 Paediatric Vaccines
    • 2.3.1.1 Prevnar/Prevenar
    • 2.3.1.2 Polio/Pertussis/Hib Vaccines (Sanofi-Aventis)
    • 2.3.1.3 Infanrix/Pediarix
    • 2.3.1.4 Varivax
    • 2.3.1.5 M-M-R II
    • 2.3.1.6 ProQuad
    • 2.3.1.7 Menactra
    • 2.3.1.8 RotaTeq
    • 2.3.1.9 Rotarix
  • 2.3.2 Other/Adult Vaccines
    • 2.3.2.1 Adacel
    • 2.3.2.2 Pneumovax
    • 2.3.2.3 Zostavax
  • 2.3.3 Influenza Vaccines
    • 2.3.3.1 Fluzone/Vaxigrip/Mutagrip
    • 2.3.3.2 Fluarix and FluLaval
    • 2.3.3.3 Fluvirin
  • 2.3.4 Prophylactic Cancer Vaccines
    • 2.3.4.1 Gardasil
    • 2.3.4.2 Cervarix
  • 2.3.5 Hepatitis Vaccines
    • 2.3.5.1 GSK Hepatitis Vaccines
    • 2.3.5.2 Havrix
    • 2.3.5.3 Engerix-B
    • 2.3.5.4 Twinrix/Ambirix
    • 2.3.5.5 Merck & Co./Sanofi Pasteur MSD Hepatitis Vaccines
    • 2.3.5.6 Vaqta/Avaxim
    • 2.3.5.7 Recombivax HB/HBvaxPRO
  • 2.3.6 Therapeutic Vaccines
    • 2.3.6.1 Grazax (ALK-Abello/Menarini)

3. The World Vaccine Market

• 3.1 World Vaccine Market Forecast, 2008-2023
  • 3.1.1 The World Vaccine Market Will Double by 2013
  • 3.1.2 Therapeutic Vaccines Will Become Established
  • 3.1.3 The World Vaccine Market, 2018-2023
• 3.2 Sales Forecast by Vaccine Class, 2008-2023
  • 3.2.1 The Leading Vaccine Classes in 2007
  • 3.2.2 Paediatric Vaccine Market Share
  • 3.2.3 Other/Adult Vaccines Sales Forecast
  • 3.2.4 Influenza Vaccines Market Growth
  • 3.2.5 Prophylactic Cancer Vaccines Market
  • 3.2.6 Hepatitis Vaccines Market
  • 3.2.7 Rapid Growth for Therapeutic Vaccines
• 3.3 Leading Vaccine Manufacturers
  • 3.3.1 A Few Major Players Dominate the Vaccine Market
  • 3.3.2 High Entry Barriers to Market
• 3.4 Sales Forecast for Leading Vaccine Brands, 2008-2013
  • 3.4.1 Leading Paediatric Vaccine Brand Forecasts, 2008-2023
    • 3.4.1.1 Prevnar/Prevenar
    • 3.4.1.2 Polio/Pertussis/Hib Vaccines
    • 3.4.1.3 Infanrix/Pediarix
    • 3.4.1.4 Varivax
    • 3.4.1.5 M-M-R II
    • 3.4.1.6 ProQuad
    • 3.4.1.7 Menactra
    • 3.4.1.8 RotaTeq
    • 3.4.1.9 Rotarix
  • 3.4.2 Leading Other/Adult Vaccine Brand Forecasts, 2008-2023
    • 3.4.2.1 Adacel
    • 3.4.2.2 Pneumovax
    • 3.4.2.3 Zostavax
  • 3.4.3 Leading Influenza Vaccine Brand Forecasts, 2008-2023
  • 3.4.4 Leading Prophylactic Cancer Vaccine Brand Forecasts, 2008-2023
    • 3.4.4.1 Gardasil
    • 3.4.4.2 Cervarix
  • 3.4.5 Leading Hepatitis Vaccine Brand Forecasts, 2008-2023

4. SWOT Analysis of the Vaccine Market

• 4.1 Analysis of the Market
• 4.2 Key Strengths of the Vaccine Industry
  • 4.2.1 Vaccines Work
  • 4.2.2 New Vaccine Technologies
    • 4.2.2.1 Vaccine Manufacturers are Expanding the Scope of Vaccines
    • 4.2.2.2 New Types of Vaccine
    • 4.2.2.3 New Adjuvants for Vaccines
    • 4.2.2.4 New Vaccine Delivery Mechanisms and Formulations
    • 4.2.2.5 Other Developments in Vaccine Technology
  • 4.2.3 New High-Margin Vaccines
  • 4.2.4 Vaccines Will Not Face Significant Generic Competition
  • 4.2.5 Personalised Vaccines
• 4.3 The Vaccines Industry: Weaknesses
  • 4.3.1 Vaccine Research and Development is Lengthy and Expensive
    • 4.3.1.1 The Vaccine Research and Development Process
    • 4.3.1.2 Vaccine Research and Development and Outsourcing
  • 4.3.2 Vaccine Manufacturing
    • 4.3.2.1 Vaccine Manufacturing has High Costs
    • 4.3.2.2 China, India and Brazil
  • 4.3.3 Consolidation of the Industry
• 4.4 Opportunities for the Vaccine Industry
  • 4.4.1 Vaccines for Diseases Currently Without a Vaccine
    • 4.4.1.1 The Most Important Non-Vaccine Preventable Diseases
    • 4.4.1.2 Cancer
    • 4.4.1.3 Dengue Fever
    • 4.4.1.4 Epstein-Barr Virus (EBV)
    • 4.4.1.5 Helicobacter Pylori Infections.
    • 4.4.1.6 Hepatitis C
    • 4.4.1.7 Hepatitis E
    • 4.4.1.8 HIV/AIDS
    • 4.4.1.9 Malaria
    • 4.4.1.10 Nosocomial Infections
    • 4.4.1.11 Respiratory Infections
    • 4.4.1.12 Roundworm and Hookworm Infections
    • 4.4.1.13 Sexually-Transmitted Diseases
    • 4.4.1.14 Tobacco
    • 4.4.1.15 West Nile Virus Infections
  • 4.4.2 Improved Vaccines for Partially Vaccine-Preventable Diseases
    • 4.4.2.1 Vaccines Effective Against More Strains
    • 4.4.2.2 Towards a Universal Influenza Vaccine
    • 4.4.2.3 The Need for an Improved Tuberculosis Vaccine
  • 4.4.3 Biodefence
    • 4.4.3.1 The Future for Bioterrorism Vaccines
    • 4.4.3.2 Pandemic-Preparedness
  • 4.4.4 Changing World Demographics
• 4.5 Key Threats Facing the Vaccine Industry
  • 4.5.1 The Anti-Vaccine Movement
    • 4.5.1.1 Misinformation about Side-Effects of Vaccines
    • 4.5.1.2 MMR Misinformation in the UK
    • 4.5.1.3 Controversy Surrounding Mercury-Containing Vaccines
    • 4.5.1.4 Campaigns Against Cervical Cancer Vaccines
    • 4.5.1.5 Consequences of Anti-Vaccine Campaigns
  • 4.5.2 Vaccines in the Developing World
    • 4.5.2.1 Vaccine Distribution Networks
    • 4.5.2.2 Vaccine Cost in Developing Countries
    • 4.5.2.3 Improving Access to Vaccines in the Developing World

5. Vaccine Country Markets

• 5.1 The Vaccine Market in 2007: Geographical Analysis
  • 5.1.1 The Commercial and Donor Vaccine Markets
  • 5.1.2 Leading Vaccine Country Markets, 2007
  • 5.1.3 Sales Forecast for Leading Vaccine Country Markets, 2008-2023
• 5.2 Leading Vaccine Country Markets
  • 5.2.1 The US Vaccine Market
    • 5.2.1.1 The US Vaccine Market, 2007
    • 5.2.1.2 The US Vaccine Market, 2008-2023
  • 5.2.2 The European Vaccine Market
    • 5.2.2.1 The German Vaccine Market
    • 5.2.2.2 The French Vaccine Market
    • 5.2.2.3 The UK Vaccine Market
  • 5.2.3 The Japanese Vaccine Market
  • 5.2.4 The Chinese Vaccine Market
    • 5.2.4.1 China is the Largest Vaccine Consumer in the World
    • 5.2.4.2 Chinese Vaccine Manufacturing
    • 5.2.4.3 Chinese Vaccine Research and Development
  • 5.2.5 The Indian Vaccine Market
    • 5.2.5.1 The Indian Vaccine Market is Rapidly Expanding
    • 5.2.5.2 India is an Important Vaccine Exporter
    • 5.2.5.3 Vaccine Research and Development in India
  • 5.2.6 The Donor Vaccine Market

6. The Vaccine Pipeline

• 6.1 The Most Promising Sectors of the Vaccines Pipeline
• 6.2 Paediatric Vaccines Pipeline
  • 6.2.1 Key Development in Paediatric Vaccines, 2008-2013
  • 6.2.2 Hexaxim
  • 6.2.3 Synflorix
  • 6.2.4 Prevnar 13
  • 6.2.5 Unifive
  • 6.2.6 MenACWY-TT
  • 6.2.7 Menveo/MenACWY-CRM
  • 6.2.8 Hib-MenCY-TT
  • 6.2.9 MenB
  • 6.2.10 Meningitis B Vaccine
  • 6.2.11 ORV 116E
• 6.3 Other/Adult Vaccines Pipeline
  • 6.3.1 Key Developments in Other/Adult Vaccines, 2008-2013
  • 6.3.2 Japanese Encephalitis Vaccines
    • 6.3.2.1 Ixiaro/IC51
    • 6.3.2.2 ChimeriVax-JE
  • 6.3.3 Adenovirus Vaccines
  • 6.3.4 Simplirix
  • 6.3.5 Flavinum
  • 6.3.6 HIV/AIDS Vaccines
    • 6.3.6.1 ALVAC-HIV/AIDSVAX B/E
    • 6.3.6.2 tgAAC09
    • 6.3.6.3 VRC-HIVADV014-00VP
  • 6.3.7 Biodefence Vaccines
    • 6.3.7.1 Anthrax Vaccine
    • 6.3.7.2 rF1V Plague Vaccine
    • 6.3.7.3 Imvamune
  • 6.3.8 CholeraGarde
  • 6.3.9 Cytomegalovirus Vaccine
  • 6.3.10 Dengue Fever Vaccines
    • 6.3.10.1 ChimeriVax-Dengue
    • 6.3.10.2 Dengue Virus Vaccine
  • 6.3.11 Mosquirix
  • 6.3.12 Nosocomial Infection Vaccines
    • 6.3.12.1 Pseudomonas Aeruginosa Vaccine
    • 6.3.12.2 V 710/Staphylococcus Aureus Vaccine
    • 6.3.12.3 ACAM-CDIFF
    • 6.3.12.4 StaphVAX
  • 6.3.13 143717A/Varicella Zoster Virus Vaccine
  • 6.3.14 Travellers' Diarrhoea Vaccines
    • 6.3.14.1 ACE393/Campylobacter Jejuni Vaccine
    • 6.3.14.2 Travellers' Diarrhoea Vaccine (Escherichia Coli)
  • 6.3.15 GSK M72/Tuberculosis Vaccine
  • 6.3.16 Typhoid Vaccine
  • 6.3.17 ChimeriVax-West Nile
• 6.4 Influenza Vaccines Pipeline
  • 6.4.1 Key Developments in Influenza Vaccines, 2008-2013
  • 6.4.2 Cell-Based Influenza Vaccines
    • 6.4.2.1 The Switch from Eggs
    • 6.4.2.2 Optaflu
    • 6.4.2.3 Influvac TC
    • 6.4.2.4 FluBlok
    • 6.4.2.5 Vero-Cell Technology
    • 6.4.2.6 Per C6
  • 6.4.3 H5N1 Influenza Vaccines
  • 6.4.4 Novel Delivery Systems for Influenza Vaccines
  • 6.4.5 New Adjuvants for Influenza Vaccines
  • 6.4.6 ACAM-FLU-A
• 6.5 Hepatitis Vaccines Pipeline
  • 6.5.1 Hepsilav/V270
  • 6.5.2 Hepatitis B Vaccine
  • 6.5.3 V 419/Hepatitis B Vaccine
  • 6.5.4 Hepatitis E Vaccine
• 6.6 Prophylactic Cancer Vaccines Pipeline
  • 6.6.1 V502/Human Papillomavirus Vaccine
  • 6.6.2 Novel Prophylactic Cancer Vaccines
    • 6.6.2.1 Epstein-Barr Virus Vaccine
    • 6.6.2.2 Helicobacter Pylori Vaccine
• 6.7 Therapeutic Vaccines Pipeline
  • 6.7.1 Therapeutic Cancer Vaccines
    • 6.7.1.1 Sipuleucel - T/Provenge
    • 6.7.1.2 TroVax
    • 6.7.1.3 MAGE-A3 ASCI
    • 6.7.1.4 Stimuvax
    • 6.7.1.5 OncoVAX
    • 6.7.1.6 MVax
    • 6.7.1.7 CDX-110
    • 6.7.1.8 Reniale
    • 6.7.1.9 Biovaxid
    • 6.7.1.10 Allovectin-7
    • 6.7.1.11 GV1001
  • 6.7.2 Therapeutic Vaccines for Hepatitis
    • 6.7.2.1 Therapeutic Hepatitis B Vaccine
    • 6.7.2.2 IC41/Hepatitis C Vaccine
    • 6.7.2.3 GI-5005/Hepatits C Treatment Vaccine
    • 6.7.2.4 ChronVac-C
  • 6.7.3 Therapeutic Vaccines for HIV Infection
  • 6.7.4 Therapeutic Vaccines for Other Viral Infections
    • 6.7.4.1 TG 4001/R3484 (MVA-HPV-IL2/HPV Vaccine)
    • 6.7.4.2 Cytomegalovirus Therapeutic Vaccine
  • 6.7.5 Therapeutic Addiction Vaccines
    • 6.7.5.1 Addiction Vaccines Will Target Nicotine and Drug Dependence
    • 6.7.5.2 NicVAX
    • 6.7.5.3 NIC002
    • 6.7.5.4 TA-NIC
    • 6.7.5.5 Niccine
    • 6.7.5.6 TA-CD
  • 6.7.6 Therapeutic Allergy Vaccines
    • 6.7.6.1 Pollinex Quattro
    • 6.7.6.2 House Dust Mite Allergy Vaccine
  • 6.7.7 Therapeutic Vaccines for Chronic Disease

7. Expert Opinion from Key Opinion-Leaders in the Vaccine Industry

• 7.1 Dr Michael Watson, Executive Vice President Research and Development, Acambis
  • 7.1.1 The Key Unmet Vaccine Needs in 2008
  • 7.1.2 The Acambis Vaccine Pipeline and the ChimeriVax Platform
  • 7.1.3 A Clostridium Difficile Vaccine
  • 7.1.4 Progress Towards a Universal Influenza Vaccine
  • 7.1.5 Improving Access to Vaccines in Developing Countries
  • 7.1.6 The Future for Biodefence Vaccines
  • 7.1.7 Highlights of the Acambis Pipeline
• 7.2 Gregory A. Poland, M.D., MACP, FIDSA, Mary Lowell Leary Endowed Professor of Medicine, Infectious Diseases, Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic (US)
  • 7.2.1 Personalised Vaccines
  • 7.2.2 Growth of Therapeutic Cancer Vaccines and Addiction Vaccines
  • 7.2.3 Ignorance and Misconceptions about Vaccines
• 7.3 Dr Raafat Fahim, President and Chief Executive Officer of Nabi Biopharmaceuticals
  • 7.3.1 Vaccines in the Pipeline for Nicotine Addiction
  • 7.3.2 Vaccines in the Pipeline for Staphylococcus, Including MRSA, Infection
  • 7.3.3 Nabi Biopharmaceuticals are Investigating the Anti-Viral RENS
• 7.4 Dr Ronald Ellis, Senior Vice President and Chief Technical Officer, NasVax, Israel
  • 7.4.1 The Key Unmet Vaccine Needs in 2008
  • 7.4.2 New Adjuvants for Influenza Vaccines
  • 7.4.3 The Future for Intranasal Vaccines
  • 7.4.4 The Vaccine Technology of the Future
  • 7.4.5 The Future for Therapeutic Vaccines
• 7.5 Dr Steen S. Klysner, Chief Executive Officer, Nordic Vaccine
  • 7.5.1 Nordic Vaccine' s Immune Enhancing Nano-Particle and Skin Patch Vaccine Technology
  • 7.5.2 Vaccine Technology in 2023
  • 7.5.3 Vaccines Will be Developed for New Diseases by 2023

8. Conclusions

• 8.1 The ‘Vaccine Boost'
• 8.2 Vaccines Will Outperform the Overall Pharmaceutical Market During 2008-2023
• 8.3 Vaccine Growth Drivers
• 8.4 Emerging Markets for Vaccines

List of Tables

• Table 2.1 Vaccine Preventable Disease Statistics
• Table 2.2 Vaccine Classes
• Table 2.3 Example Brands for Polio/Pertussis/Hib Vaccines (Sanofi-Aventis*)
• Table 2.4 Brands in the Infanrix/Pediarix Range of Vaccines
• Table 3.1 Worldwide Vaccine Market ($bn), 2007-2013
• Table 3.2 Worldwide Vaccine Market ($bn), 2014-2023
• Table 3.3 Vaccines Sales ($bn) and Market Share by Vaccine Class, 2007
• Table 3.4 Vaccines Sales ($bn) by Vaccine Class, 2007-2013
• Table 3.5 Vaccines Sales ($bn) by Vaccine Class, 2014-2023
• Table 3.6 Leading Vaccine Manufacturers, 2007
• Table 3.7 Leading Paediatric Vaccine Sales ($bn), 2007-2013
• Table 3.8 Leading Other/Adult Vaccine Sales ($bn), 2007-2013
• Table 3.9 Leading Influenza Vaccine Sales ($bn), 2007-2013
• Table 3.10 Gardasil Sales ($bn), 2007
• Table 3.11 Leading Prophylactic Cancer Vaccine Sales ($bn), 2007-2013
• Table 3.12 Leading Hepatitis Vaccine Sales ($bn), 2007-2013
• Table 4.1 SWOT Chart for Vaccines Market
• Table 4.2 Selected Diseases Currently Without a Vaccine
• Table 4.3 Population Statistics 2007-2023
• Table 4.4 GDP China, India, US and Japan, 2007-2023
• Table 5.1 Commercial & Donor Vaccine Market, 2007
• Table 5.2 Leading Vaccines Country Markets 2007
• Table 5.3 Vaccines Sales Forecast ($bn) for Leading Country Markets, 2007-2013
• Table 5.4 Vaccines Sales Forecast ($bn) for Leading Country Markets, 2014-2023
• Table 6.1 Key Pipeline Paediatric Vaccines
• Table 6.2 Key Pipeline Other/Adult Vaccines
• Table 6.3 Key Cell-Culture Influenza Vaccines
• Table 6.4 Key Pipeline Hepatitis Vaccines
• Table 6.5 Key Pipeline Prophylactic Cancer Vaccines
• Table 6.6 Key Pipeline Therapeutic Cancer Vaccines
• Table 6.7 Key Pipeline Therapeutic Hepatitis Vaccines
• Table 6.8 Key Pipeline Therapeutic HIV/AIDS Vaccines
• Table 6.9 Key Pipeline Therapeutic Addiction Vaccines

List of Figures

• Figure 3.1 Worldwide Vaccine Market ($bn), 2007-2023
• Figure 3.2 Market Share by Vaccine Class, 2007
• Figure 3.3 Paediatric Vaccine Sales ($bn), 2007-2023
• Figure 3.4 Sales ($bn) by Vaccine Class (Excluding Paediatric Vaccines), 2007-2023
• Figure 3.5 Vaccine Sales ($bn) and Market Share by Vaccine Class, 2007-2023
• Figure 3.6 Market Share by Vaccine Class, 2013
• Figure 3.7 Market Share by Vaccine Class, 2018
• Figure 3.8 Market Share by Vaccine Class, 2023
• Figure 3.9 Leading Vaccine Manufacturers, 2007
• Figure 3.10 Prevnar/Prevenar Sales ($bn), 2007-2013
• Figure 3.11 Leading Paediatric Combination Vaccine Sales ($bn), 2007-2013
• Figure 3.12 Varivax, M-M-R II and ProQuad Sales ($bn), 2007-2013
• Figure 3.13 Menactra Sales ($bn), 2007-2013
• Figure 3.14 RotaTeq and Rotarix Sales ($bn), 2007-2013
• Figure 3.15 Adacel Sales ($bn), 2007-2013
• Figure 3.16 Pneumovax Sales ($bn), 2007-2013
• Figure 3.17 Zostavax Sales ($bn), 2007-2013
• Figure 3.18 Leading Influenza Vaccine Sales ($bn), 2007-2013
• Figure 3.19 Leading Prophylactic Cancer Vaccine Sales ($bn), 2007-2013
• Figure 3.20 Leading Hepatitis Vaccine Sales ($bn), 2007-2013
• Figure 4.1 Population of China, India, US and Germany, 2007-2023
• Figure 4.2 Gross Domestic Product ($tr) for US, Japan, China and India, 2007-2023
• Figure 5.1 Commercial and Donor Vaccine Market Share, 2007
• Figure 5.2 Vaccine Market Share by Leading Country, 2007
• Figure 5.3 Vaccines Sales for Leading Country Markets 2007-2023: Upper Group
• Figure 5.4 Vaccines Sales for Leading Country Markets 2007-2023: Lower Group
• Figure 5.5 Vaccine Market Share by Leading Country, 2013
• Figure 5.6 Vaccine Market Share by Leading Country, 2018
• Figure 5.7 Vaccine Market Share by Leading Country, 2023

Companies Listed

• Acambis
• Accentia Biopharmaceuticals
• ACE BioSciences
• Advisory Committee on Immunization Practices (ACIP) [US]
• Aeras Global TB Vaccine Foundation
• ALK-Abello
• Allergy Therapeutics
• AnGes MG
• Antigenics
• Astellas
• AstraZeneca
• AVANT Immunotherapeutics
• Avax Technologies
• Barr
• Bavarian Nordic
• Baxter
• Bharat Biotech
• Bill & Melinda Gates Foundation
• Biogen Idec
• Biological E.
• Biotecnol
• Celtic Pharma
• Centers for Disease Control and Prevention (CDC) [US]
• China National Biotec Group
• Chiron (acquired by Novartis in 2006)
• Computer Sciences Corporation (CSC)
• Crucell
• CSL
• Cytos Biotechnology
• Daiichi Sankyo
• Dendreon
• Diamyd Medical
• Dynavax
• DynPort Vaccine Company (DVC) [subsidiary of Computer Sciences Corporation (CSC)]
• Emergent Biosolutions
• European Medicines Agency (EMEA)
• Food and Drug Administration (FDA)
• GAVI Alliance
• Genelabs
• Genetic Immunity
• GenVec
• GlaxoSmithKline (GSK)
• GlobeImmune
• Green Cross [Korea]
• Independent Pharmaceutica
• Inovio Biomedical
• Intercell
• International AIDS Vaccine Initiative
• Intracel
• Kaketsuken
• Karolinska Institutet [Sweden]
• LipoNova
• Lonza
• MedImmune (acquired by AstraZeneca in 2007)
• Menarini
• Merck & Co.
• Merck KGaA
• Mitsubishi Tanabe
• Nabi Biopharmaceuticals
• NasVax [Israel]
• National Institute of Allergy and Infectious Diseases (NIAID) [US]
• Novartis
• Novavax
• Oncothyreon
• Oxford BioMedica
• Pan American Health Organization (PAHO)
• Petrovax
• Pfizer
• PharmAthene
• Pharmexa
• Protein Sciences
• Ranbaxy
• Roche
• Sanofi Pasteur MSD [joint venture between Merck & Co. and Sanofi-Aventis]
• Sanofi-Aventis
• Schering-Plough
• Serum Institute of India
• Sinovac
• Solvay
• Targeted Genetics
• Therapeutic Goods Administration [Australia]
• Transgene
• Tripep
• UMN Pharma
• UNICEF (United Nations Children' s Fund)
• University of Queensland [Australia]
• US Census Bureau
• Vaccine Research Center (VRC) [part of NIAID, US]
• Vaccinogen
• VaxGen
• Vaxine [Australia]
• Vical
• Virax
• Worldwide Health Organization (WHO)
• Wyeth
• Wistar Institute [US]
• Ludwig Institute of Cancer Research
• Xenova (acquired by Celtic Pharma in 2005)

相關商品

疫苗相關市場調查報告書

大腸癌、血管增生、癌症疫苗分析
Triple Analysis: Colorectal Cancer, Angiogenesis and Cancer Vaccines
價格 : US $ 5175
出版日期 : 2012年01月

白血病、血管增生、癌症疫苗：藥劑開發策略分析
Triple Analysis: Leukemia, Angiogenesis and Cancer Vaccines
價格 : US $ 5175
出版日期 : 2012年01月

淋巴癌、血管增生、癌症疫苗：藥劑開發策略分析
Triple Analysis: Lymphoma, Angiogenesis and Cancer Vaccines
價格 : US $ 5175
出版日期 : 2012年01月

Visiongain發行的製藥相關市場調查報告書

抗菌藥物：全球市場展望 2012-2022

Antibacterial Drugs: World Market Prospects 2012-2022

價格 : US $ 2642

出版日期 : 2011年11月

多發性硬化症治療：全球藥劑市場 2012-2022

Multiple Sclerosis Treatment: World Drug Market 2012-2022

價格 : US $ 2642

出版日期 : 2011年11月

全球小分子癌症標靶治療市場：2011-2021

Small-Molecule Targeted Cancer Therapies: World Market 2011-2021

價格 : US $ 2642

出版日期 : 2011年11月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!